Assessment of Biosimilarity in mAb-based Therapeutics Using SEC-MALS

Applications | 2025 | WatersInstrumentation
GPC/SEC
Industries
Pharma & Biopharma
Manufacturer
Waters
Downloadable PDF for viewing
 

Similar PDF

EC-MALS for absolute biophysical characterization
Multi-Attribute Quantitation of Antibody-Drug Conjugates by LC-MALS
Enhanced SEC-MALS analysis of therapeutic mAbs, biosimilars and AAVs with XBridge Premier columns
The Role of Multi-Angle Light Scattering in Biosimilar Characterization and Approval